Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06967961

Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers

A prospective, proof-of-concept pilot study in patients with metastatic cancers (9 types of cancers are studied) treated at the IUCT-O or possibly in other institutions. Eligible patients will be selected and informed of this study during a medical consultation for their cancer by medical oncologists. Then, with the patient's consent and before the start of anti-cancer treatment (whatever the line), a blood sample will be taken to detect DP-circulating cells by 2 different methods of analysis.

Each patient will participate in the study for one day. The methods of analysis will be: flow cytometry for all patients and either Parsotix® or CellSearch® depending on the type of cancer.

450 patients will be enrolled in total.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Urothelial Carcinoma Adenocarcinoma of Endometrium Carcinoma Carcinoma, Transitional Cell Cervical Carcinoma Cutaneous Melanoma Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Kidney Diseases Kidney Neoplasms Male Urogenital Diseases Melanoma Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Connective and Soft Tissue Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neuroectodermal Tumors Neuroendocrine Tumors Nevi and Melanomas Nonseminomatous Germ Cell Tumor Prostate Adenocarcinoma Renal Cancer Sarcoma Seminomatous Germ Cell Tumor Skin Diseases Skin Neoplasms Skin and Connective Tissue Diseases Soft Tissue Sarcoma (STS) Upper Aerodigestive Tract Carcinoma Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms Uterine Cervical Diseases Uterine Cervical Neoplasms Uterine Diseases Uterine Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Oncopole Claudius Regaud, IUCT-O

Toulouse, 31059, France

Location status: Recruiting

Location contact

Thibaud VALENTIN, MD

CONTACT

[email protected]

0033 5 31 15 51 70

Thibaud VALENTIN, MD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1. Patients with one of the following cancer types: urothelial carcinoma, renal carcinoma, prostate adenocarcinoma, upper aerodigestive tract carcinoma, cervival carcinoma, adenocarcinoma of endometrium, cutaneous melanoma, soft tissue sarcoma, seminomatous and nonseminomatous germ cell tumors
  • 2. Metastatic disease for which the treatment (whatever the line) has not been initiated yet
  • 3. Age ≥ 18 years
  • 4. Patient affiliated to a French Social Security scheme
  • 5. Patient having signed his/her informed consent prior to inclusion in the study and prior to any specific procedure for the study.

Exclusion criteria

  • 1. Patient with localized disease.
  • 2. Pregnant or breast-feeding women.
  • 3. Any psychological, family, geographical or sociological condition that prevents compliance with the medical monitoring and/or procedures set out in the study protocol.
  • 4. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).

Treatment and study plan

For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes:

Other

A blood sample will be taken before initiation of the metastatic treatment line and will be analyzed by 2 distinct methods. The total blood volume withdrawn per patient is approximately 30mL.

Primary outcomes

  1. Rate of patients presenting blood circulating DP cells detected by at least one of the two tested techniques (Flow Cytometry/ CellSearch® or Parsortix® according to the type of tumor)

    Time frame: 1 year after the Last Patient Last Visit

    It is defined as the ratio of number of patients for whom DP cells were detected (by at least 1 of the 2 techniques) by the total number of patients.

Secondary outcomes

  1. Rate of patients presenting blood circulating DP cells detected by each method of analysis (Flow Cytometry and CellSearch® or Parsortix® according to the tumor type)

    Time frame: 1 year after the Last Patient Last Visit

    It is defined as the ratio of the number of patients presenting DP cells (detected by the concerned technique) by the total number of patients

Study contacts

Contact information is provided by the study sponsor or research team.

Thibaud VALENTIN, MD

CONTACT

[email protected]

0033 5 31 15 51 70

Sponsors and collaborators

Lead sponsor

Institut Claudius Regaud

Other

Registry information

Acronym: DP-PAN-CANCER

Important dates

Study start
2025
Primary completion
2029
Study completion
2029
First posted
May 13, 2025
Registry last updated
Jun 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.